Daiichi Sankyo US Social Media Community Guidelines

Looking for more about Daiichi Sankyo US? Follow us on social media!

We use social media in the U.S. to share stories about our innovations, company, culture and provide the latest news related to our medicines. We appreciate the opportunity to connect with you and ask that if you leave a comment or ask a question, please follow these Community Guidelines to ensure everyone has the best experience possible.

We work in a highly‐regulated industry with unique legal considerations. Therefore, we are not permitted to engage in discussions about our medicines, other company information or provide guidance on treatment options. These discussions should be held privately with a health care professional.

Because of these regulations, we may delete, hide or not respond to comments on our channels that, in Daiichi Sankyo’s sole discretion:

• Name our or other companies’ products (including those in clinical trials)
• Offer health or medical advice
• Contain personal information (e.g. names, phone numbers, personal videos, etc.)
• Contain proprietary, confidential, sensitive, or nonpublic information
• Are disparaging, harassing, threatening, profane, abusive, false, misleading, condone violence or illegal behavior, or that are otherwise disruptive to the community
• Are commercial in nature, including but not limited to those related to sales, recruitment, or promotion of any kind
• Are or could be construed as copyright infringement or other intellectual property violations
• Violate the platform’s terms of service (see below tabs for platform specific information)

Daiichi Sankyo US’s engagement with other accounts or their content shall not be construed as an endorsement of any kind or otherwise indicate of the existence of a business relationship. Daiichi Sankyo is not responsible for and does not assume any liability for any third-party content. Nothing provided on these channels constitutes an offer or invitation to invest or deal in Daiichi Sankyo securities.

Reporting side effects or adverse reactions

If you believe you have experienced a medical side effect from a Daiichi Sankyo medicine, please consult your physician, pharmacist, or other healthcare professional immediately. We encourage you to report any product issues or questions to our Contact Center at 1-877-4 DS-PROD (1-877-437-7763). Health professionals, consumers and patients can voluntarily report observed or suspected adverse events for human medical products to FDA at www.fda.gov/medwatch or by calling 1-800-FDA-1088.

It is not recommended to share any specific personal or health related information on social media. Please be aware that Daiichi Sankyo may need to contact any individual who includes a post with details related to any medical side effects or product issues to find out more information. Posts with sensitive personal health information shared on a Daiichi Sankyo US page may be removed due to legal obligations concerning drug safety reporting.

Using and storing personal identifying information

Daiichi Sankyo will not disclose or share personal identifying information on its social channels unless we have obtained proper consent. In the case of reporting a side effect or product issue, we will need to store and use personal identifying information, such as your name, location, health‐related information or similar, in accordance with applicable laws. This information is required to be submitted to the Daiichi Sankyo Pharmacovigilance and Patient Safety department and/or regulatory authorities, and stored for auditing purposes.

In some instances, Daiichi Sankyo may choose to use third‐party service providers to help us manage comments and messages, which means that they too would have access to any personal identifying information you share with us. Such third‐party service providers are contractually bound and trained to ensure an adequate protection and security of your personal identifying information.

Thank you for your cooperation and for being a part of the Daiichi Sankyo US social media community.